U.S. Health Secretary Robert F.

U.S. Health Secretary Robert F.

U.S. Health Secretary Robert F.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy.

New analysis shows the number of measles cases reported in the U.S. this year just surpassed 1,000.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax.

A video shows a Texas doctor, who has been treating children in a measles outbreak, with a measles rash on his face in a clinic while caring for patients a week before he met with Health Secretary Robert F.

The top vaccine official with the Food and Drug Administration has resigned and criticized the nation's top health official for allowing “misinformation and lies” to guide his thinking behind the safety of vaccinations.

Robert F.

Food and Drug Administration nominee Dr. Marty Makary is known for his contrarian views and fiery criticism of traditional medical institutions.

Newly installed Health and Human Services Secretary Robert F.

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot.

A federally funded study has found a possible link between aluminum in some childhood vaccines and persistent asthma, but experts say the study has several shortcomings.

A new government report shows Pfizer’s COVID-19 vaccine gave children 5 and older strong protection against hospitalization and death even during the omicron surge.

The omicron-fueled surge that is sending COVID-19 cases rocketing in the U.S. is putting children in the hospital in record numbers.

A study of health care workers in South Africa found that two doses of Johnson & Johnson’s COVID-19 vaccine offer 85% protection against hospitalizations from the omicron variant, ABC News reported Thursday.

President Joe Biden’s administration drew up a strategy to contain one coronavirus strain, then another showed up that’s much more contagious.

The world’s leading COVID-19 vaccines may offer lasting protection that diminishes the need for frequent booster shots.

FILE - This September 2020, file photo provided by Johnson & Johnson shows a pharmacist preparing to give an experimental COVID-19 vaccine. (Johnson & Johnson via AP, File)WASHINGTON – U.S. health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic. One challenge in rolling out the new vaccine will be explaining how protective the J&J shot is after the astounding success of the first U.S. vaccines. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. On Sunday, a CDC panel is expected to meet to recommend how to best prioritize use of the J&J vaccine.

FILE - This Dec. 2, 2020 photo provided by Johnson & Johnson shows vials of the Janssen COVID-19 vaccine in the United States. “I was reassured” that despite different variants, the J&J shot still protected against serious illness, said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. Across all countries, the analysis of the J&J vaccine showed protection began to emerge about 14 days after vaccination. Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache. AdIf the FDA clears the J&J shot for U.S. use, it will not boost vaccine supplies significantly right away.

Correction: Virus Outbreak-Vaccine storyPublished: December 11, 2020, 9:30 pm Updated: December 14, 2020, 11:58 amFull Screen 1 / 7 The Pfizer Global Supply Kalamazoo manufacturing plant is shown in Portage, Mich., Saturday, Dec. 12, 2020. (AP Photo/Paul Sancya)WASHINGTON – In a story December 12, 2020, about COVID-19 vaccines, The Associated Press erroneously identified one of the companies involved in the initial rollout at nursing homes and assisted living centers. It is Walgreens, not Rite Aid. Copyright 2020 The Associated Press. This material may not be published, broadcast, rewritten or redistributed without permission.

MIAMI – The U.S. gave the final go-ahead Friday to the nation’s first COVID-19 vaccine, marking what could be the beginning of the end of an outbreak that has killed nearly 300,000 Americans. On Saturday, The FDA held a press conference about allowing emergency use of the vaccine. The U.S. is considering a second vaccine, made by Moderna Inc., that could roll out in another week. Globally, Sahin said production should scale up considerably in February, with the companies projecting 120 million to 130 million doses a month to reach 1.3 billion doses in 2021. In addition, the FDA insisted that large COVID-19 vaccine studies track at least half the participants for two months to look for side effects, a time period when historically any vaccine problems appear.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. As a result, the expert panel wrestled with a list of questions that have yet to be answered. The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

Anticipating that, a Food and Drug Administration advisory panel is on standby to publicly debate the data in early December. The companies also have begun “rolling submissions” for the vaccine with regulators in Europe, the U.K. and Canada and soon will add this new data. Pfizer and BioNTech had initially estimated the vaccine was more than 90% effective after counting a group of the earliest infections that occurred in its final-stage testing. Pfizer would handle shipping of its own doses; the warp speed program will help with support and distributing additional companies' vaccines if and when they become available. Pfizer and BioNTech said they expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses in 2021.

University of Hong Kong scientists claim to have the first evidence of someone being reinfected with the virus that causes COVID-19. The man had mild symptoms the first time and none the second time; his more recent infection was detected through screening and testing at the Hong Kong airport. It shows that some people do not have lifelong immunity to the virus if they've already had it, To said. If there is a reinfection, it suggests the possibility there was residual immunity ... that helped protect the patient from getting sick again, Goodman said. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education.